Why the study?
Patients with SLE have increased CVD risk and frequent sub-clinical atherosclerosis, but standard serum lipid measurements do not predict this risk.
Can serum metabolomics analysis predict the presence of sub-clinical atherosclerosis in patients with systemic lupus erythematosus?
Can serum metabolomics analysis predict the presence of sub-clinical atherosclerosis in patients with systemic lupus erythematosus?
Serum metabolomics, specifically VLDL subclasses, may serve as a promising biomarker for predicting sub-clinical atherosclerosis in patients with SLE.
Metabolomic VLDL profiling may support subclinical atherosclerosis prediction in SLE; hypothesis-generating and requires prospective validation before clinical adoption.
Background Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD) and 30-40% have sub-clinical atherosclerosis on vascular ultrasound scanning. Standard measurements of serum lipids in clinical practice do not predict CVD risk in patients with SLE. We hypothesise that more detailed analysis of lipoprotein taxonomy could identify better predictors of CVD risk in SLE. Methods Eighty patients with SLE and no history of CVD underwent carotid and femoral ultrasound scans; 30 had atherosclerosis plaques (SLE-P) and 50 had no plaques (SLE-NP). Serum samples obtained at the time of the scan were analysed using a lipoprotein-focused metabolomics platform assessing 228 metabolites by nuclear magnetic resonance spectroscopy. Data was analysed using logistic regression and five binary classification models with 10-fold cross validation; decision tree, random forest, support vector machine and lasso (Least Absolute Shrinkage and Selection Operator) logistic regression with and without interactions. Results Univariate logistic regression identified four metabolites associated with the presence of sub-clinical plaque; three subclasses of very low density lipoprotein (VLDL) (percentage of free cholesterol in medium and large VLDL particles and percentage of phospholipids in chylomicrons and extremely large VLDL particles) and Leucine. Together with age, these metabolites were also within the top features identified by the lasso logistic regression (with and without interactions) and random forest machine learning models. Logistic regression with interactions differentiated between SLE-P and SLE-NP with greatest accuracy (0.800). Notably, percentage of free cholesterol in large VLDL particles and age were identified by all models as being important to differentiate between SLE-P and SLE-NP patients. Conclusion Serum metabolites are a promising biomarker for prediction of sub-clinical atherosclerosis development in SLE patients and could provide novel insight into mechanisms of early atherosclerosis development.
No takes yet. Share an insight, caveat, or question.
Coelewij et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: